Penn Vet | Clinical Trial Detail - DERMATITIS - Randomized clinical trial to assess the utility of feline Interleukin-2 as an adjuvant to allergen vaccines, for the treatment of feline atopic dermatitis.
Contact
New Bolton Center Kennett Square, PA
Emergencies & Appointments:
610-444-5800
Directions
Ryan Hospital Philadelphia, PA
Emergencies:
215-746-8911
Appointments:
215-746-8387
Directions

DERMATITIS - Randomized clinical trial to assess the utility of feline Interleukin-2 as an adjuvant to allergen vaccines, for the treatment of feline atopic dermatitis.

Jul 2, 2019

The purpose of this study is to assess the efficacy of a novel immunotherapy, Interleukin-2, to improve the feline immune response to allergy shots. Enrolled cats will be randomized to receive the novel immunotherapy or placebo; however, all cats will receive standard-of-care allergen vaccines ("allergy shots") at no charge for 12 months. Cats will have approximately 8 visits to Penn Vet over the course of approximately 1 year.

Eligibility:

  • Healthy cats over 1 year of age
  • Cats already having gone through an adequate hypoallergenic diet trial
  • Cats tolerant to several veterinary visits
  • Use of an investigator-approved flea preventative throughout the trial period
  • Clinical diagnosis of Atopic Dermatitis
  • Owners must be willing and able to administer allergy shots at home

Benefits:

All study visits, including intradermal allergy testing to confirm allergy and allergy shots, are covered by the study.

For more information, contact the Veterinary Clinical Investigations Center at 215-573-0302 or vcic@vet.upenn.edu.